International journal of psychiatry in clinical practice
July 10, 2025
Stefan Jerotić, Milica Nestorovic, Janko Nešić et al.
3 citations
In two male patients with treatment-resistant depression, a structured interview assessing their felt sense of time (TATE) detected improvements in subjective experience before a standard depression rating scale (MADRS) did. One patient's TATE scores reached general population levels at week 4, one week earlier than the MADRS indicated treatment response. These cases suggest that phenomenological assessments can capture nuanced early improvements that traditional scales may miss, offering a complementary tool for monitoring treatment effectiveness.
Psychopathology
January 1, 2025
Stefan Jerotić, Janko Nešić, Vuk Vuković et al.
3 citations
Psychopharmacology is often reduced to treating biological symptoms while ignoring patients' subjective, embodied experience. This paper proposes an enactive and embodied framework that integrates phenomenology, neuroscience, and physiology to understand how psychotropic drugs affect the entire lived body—altering emotional processing, perception, existential feelings, and the embodied sense of self. Medications shape how patients engage with their environment, which in turn influences the embodied system. The clinician's role is to mediate these embodied changes, supporting patients through shifts in self-perception and relationality. The authors advocate for phenomenological drug profiles and patient-centered interventions that account for subjective and embodied changes alongside clinical efficacy.
Neuroscience Applied
January 1, 2025
Stefan Jerotić
2 citations
No Summary
Medicinska istrazivanja
January 1, 2026
Stefan Jerotić, Olga Čolović, Nađa Marić
Psychedelic-assisted psychotherapy (PAP) shows promise for treating major depressive disorder and post-traumatic stress disorder, but the specific role of psychotherapy within PAP remains unclear. This narrative review describes the development of PAP in Western psychiatry, outlines the standard therapeutic framework of preparation, dosing, and integration, and synthesizes findings from recent randomized controlled trials with psilocybin and MDMA. Although these trials report significant clinical benefit, they vary widely in therapeutic orientation, manualization, and therapist involvement.